MorphoSys Signs a Broad-Based Agreement for Use of Antibody Technologies with Merck & Co., Inc.
15-Dec-2005 -
MorphoSys AG announced that it has signed a five-year license agreement with U.S. pharmaceutical company Merck & Co., Inc. for the use of MorphoSys's HuCAL GOLD® and AutoCAL(TM) technologies in research and development of human therapeutic antibodies.
Under the terms of the agreement, MorphoSys ...
human antibodies
license agreements
Merck
+3